MX2010012141A - Encapsulacion de agentes biologicamente activos. - Google Patents

Encapsulacion de agentes biologicamente activos.

Info

Publication number
MX2010012141A
MX2010012141A MX2010012141A MX2010012141A MX2010012141A MX 2010012141 A MX2010012141 A MX 2010012141A MX 2010012141 A MX2010012141 A MX 2010012141A MX 2010012141 A MX2010012141 A MX 2010012141A MX 2010012141 A MX2010012141 A MX 2010012141A
Authority
MX
Mexico
Prior art keywords
biologically active
antibody
active agent
particulate carrier
nanoparticles
Prior art date
Application number
MX2010012141A
Other languages
English (en)
Spanish (es)
Inventor
Irene Papanicolaou
Mehmet Fidanboylu
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2010012141A publication Critical patent/MX2010012141A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010012141A 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos. MX2010012141A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5077508P 2008-05-06 2008-05-06
US7417108P 2008-06-20 2008-06-20
PCT/EP2009/055437 WO2009135854A2 (en) 2008-05-06 2009-05-05 Encapsulation of biologically active agents

Publications (1)

Publication Number Publication Date
MX2010012141A true MX2010012141A (es) 2010-12-17

Family

ID=43125568

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012141A MX2010012141A (es) 2008-05-06 2009-05-05 Encapsulacion de agentes biologicamente activos.

Country Status (11)

Country Link
US (1) US20110059167A1 (https=)
EP (1) EP2271324A2 (https=)
JP (1) JP2011519893A (https=)
CN (1) CN102083423A (https=)
AU (1) AU2009245785A1 (https=)
BR (1) BRPI0912536A2 (https=)
EA (1) EA201001567A1 (https=)
IL (1) IL208666A0 (https=)
MX (1) MX2010012141A (https=)
WO (1) WO2009135854A2 (https=)
ZA (1) ZA201007437B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110064819A1 (en) * 2008-05-06 2011-03-17 Andrew Beaton Encapsulation of biologically active agents
US9802984B2 (en) 2013-06-07 2017-10-31 The Johns Hopkins University Biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
EP3377115A2 (en) * 2015-11-20 2018-09-26 AbbVie Deutschland GmbH & Co. KG Surface-modified nanospheres encapsulating antigen-binding molecules
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3462193A (en) * 1993-02-15 1994-08-29 Shield Research Limited Polyalkylcyanoacrylate nanocapsules
ES2152990T3 (es) * 1993-09-09 2001-02-16 Schering Ag Principios activos y microparticulas que contienen gases.
AU7134898A (en) * 1997-04-17 1998-11-11 Amgen, Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US20030152636A1 (en) * 2000-02-23 2003-08-14 Nanopharm Ag Method of treating cancer
US7332159B2 (en) * 2004-09-30 2008-02-19 Board Of Regents Of The University Of Nebraska Method and composition for inhibiting reperfusion injury in the brain
US7597907B2 (en) * 2004-11-05 2009-10-06 Trustees Of The University Of Pennsylvania Antioxidant polymer nanocarriers for use in preventing oxidative injury

Also Published As

Publication number Publication date
EP2271324A2 (en) 2011-01-12
WO2009135854A2 (en) 2009-11-12
WO2009135854A3 (en) 2010-11-04
US20110059167A1 (en) 2011-03-10
BRPI0912536A2 (pt) 2018-10-16
IL208666A0 (en) 2010-12-30
JP2011519893A (ja) 2011-07-14
AU2009245785A1 (en) 2009-11-12
EA201001567A1 (ru) 2011-08-30
CN102083423A (zh) 2011-06-01
ZA201007437B (en) 2012-03-28

Similar Documents

Publication Publication Date Title
EP2441447A1 (en) Encapsulation of biologically active agents
MX2010012136A (es) Encapsulacion de agentes biologicamente activos.
Zaman et al. Nanoparticle formulations that allow for sustained delivery and brain targeting of the neuropeptide oxytocin
JP5484339B2 (ja) 合成物の持続的な放出のためのデンドリマー
Ye et al. Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits
Kim et al. Intraocular distribution and kinetics of intravitreally injected antibodies and nanoparticles in rabbit eyes
CN109890964A (zh) 核酸、蛋白和小分子在玻璃体囊泡体中的递送
JP2025128118A (ja) 非水性エマルションを使用した持続放出製剤
MX2010012141A (es) Encapsulacion de agentes biologicamente activos.
MX2010012137A (es) Encapsulacion de agentes biologicamente activos.
CN105338961A (zh) 制备包含治疗性蛋白质的颗粒的方法
Eldem et al. Ocular drug, gene and cellular delivery systems and advanced therapy medicinal products
US20230293348A1 (en) Dyes for use in a method of photoporation of the inner limiting membrane
Zhang Kinetics of polymeric nanoparticulate carriers and cargo under physiological and pathological conditions in the retina
Natarajan et al. Drug, delivery and devices for diabetic retinopathy (3Ds in DR)